Socioeconomic position is associated with N-terminal pro-brain natriuretic peptide (NT-proBNP)-Results of the population-based Heinz Nixdorf Recall study.

Autor: Marina Rudman, Mirjam Frank, Carina Emmel, Emanuel Matusch, Kaffer Kara, Amir Abbas Mahabadi, Raimund Erbel, Karl-Heinz Jöckel, Nico Dragano, Börge Schmidt

Publikováno v: PLoS ONE, Vol 16, Iss 8, p e0255786 (2021)

ObjectivesN-Terminal pro Brain Natriuretic Peptide (NT-proBNP) is a diagnostic marker for heart failure and a prognostic factor for cardiovascular disease (CVD). The aim of this study was to examine the association of socioeconomic position (SEP) wit

Externí odkaz: https://doaj.org/article/33b0421ed5524dfdb38fb56d820f6ff9

NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study

Autor: Henrik Rudolf, Andreas Mügge, Hans J. Trampisch, Hubert Scharnagl, W. März, Kaffer Kara

Publikováno v: International Journal of Cardiology: Heart & Vasculature, Vol 29, Iss , Pp 100553- (2020)

Background: Beside their role in the diagnosis of heart failure in symptomatic patients with dyspnea, natriuretic peptides have been suggested to improve risk prediction of cardiac events and mortality in asymptomatic cohorts. We aimed to evaluate th

Externí odkaz: https://doaj.org/article/16439046777e4d089240a95f9b8e9bb4

Outcomes after transcatheter aortic valve replacement in older patients

Autor: Andreas Mügge, Aydan Ewers, Peter L. Haldenwang, Nikolaos Patsalis, Dominik Schöne, Axel Kloppe, Leif Bösche, Assem Aweimer, Justus Strauch, Kaffer Kara, Habib Erdogan, Polykarpos C. Patsalis, Fabian Schiedat

Publikováno v: Herz

The prevalence of aortic valve stenosis is increasing due to the continuously growing geriatric population. Data on procedural success and mortality of very old patients are sparse, raising the question of when this population may be deemed as "too o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0afc8886716633555c9173efb84c2b
https://doi.org/10.1007/s00059-020-04986-0

Undersizing but overfilling eliminates the gray zones of sizing for transcatheter aortic valve replacement with the balloon-expandable bioprosthesis

Autor: Björn Plicht, Dominik Schöne, Kaffer Kara, Peter L. Haldenwang, Polykarpos C. Patsalis, Assem Aweimer, Justus Strauch, Fabian Schiedat, Andreas Mügge, Axel Kloppe, Thomas Buck

Publikováno v: International Journal of Cardiology: Heart & Vasculature, Vol 30, Iss, Pp 100593-(2020)
International Journal of Cardiology. Heart & Vasculature

Highlights • Transcatheter heart valve size selection is still challenging. • The overlap between two different prosthesis sizes for borderline annuli remains. • Undersizing but overfilling improves sizing in borderline annulus cases. • Under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86c9697ec8a645390aff09a53faa8dca
https://pubmed.ncbi.nlm.nih.gov/32775601

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial

Autor: Dirk Sibbing, Dániel Aradi, Claudius Jacobshagen, Lisa Gross, Dietmar Trenk, Tobias Geisler, Martin Orban, Martin Hadamitzky, Béla Merkely, Róbert Gábor Kiss, András Komócsi, Csaba A Dézsi, Lesca Holdt, Stephan B Felix, Radoslaw Parma, Mariusz Klopotowski, Robert H G Schwinger, Johannes Rieber, Kurt Huber, Franz-Josef Neumann, Lukasz Koltowski, Julinda Mehilli, Zenon Huczek, Steffen Massberg, Zofia Parma, Maciej Lesiak, Anna Komosa, Michal Kowara, Bartosz Rymuza, Lukasz Malek, Daniel Aradi, Gábor Veress, András Döme Dézsi, Árpád Lux, Judit Papp, Andrea Kovács, Csaba András Dézsi, Sayour Amer, Zoltán Ruzsa, Szilárd Róna, Renáta Ili, Imre Ungi, Ferenc Nagy, Robert Zweiker, Gábor Tóth-Gayor, Paul Haller, Wolfgang von Scheidt, Andreas Blüthgen, Stefan Leggewie, Hans Ulrich Kreider-Stempfle, Thomas Remp, Kaffer Kara, Andreas Mügge, Alexander Wutzler, Stephan Fichtlscherer, Andreas M. Zeiher, Florian Seeger, Martin Hinterseer, Andreas König, Susanne Lederle, Frauke Czepluch, Lars Maier, Wolfgang Schillinger, Samuel Sossalla, Astrid Hummel, Stephan Felix, Mahir Karakas, Karsten Sydow, Tanja Rudolph, Marcel Halbach, Tommaso Gori, Thomas Münzel, Andreas May, Carsten-Manuel Gerstenberg, David Pilecky, Markus Deichstetter, Stefan Kääb, Anja Löw, Matthias Orban, Stefan Sattler, Sabine Deuschl, Daniel Teupser, Harald Mudra, Thomas Räder, Torsten Schütz, Felix Vahldiek, Dimitar Divchev, Hüseyin Ince, Christoph A Nienaber, Henning Radunski, Peter Boekstegers, Jan Horstkotte, Ralf Mueller, Karin Müller, Robert Schwinger, Oliver Rasp

Publikováno v: The Lancet. 390:1747-1757

Summary Background Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest anti-ischaemic benefit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da8e32d8b43c8d025c74ebb3eff4fcf
https://doi.org/10.1016/s0140-6736(17)32155-4